When does Caplyta (lumateperone) patent protection expire?
Public patent timelines for Caplyta vary by patent family (active ingredient, formulation, and specific method-of-use claims), so there is no single universal “expiration date.” Patent protection generally ends when the last relevant patent in the relevant jurisdiction expires, and that date can be different from first commercial launch dates or from exclusivity granted by regulators.
For a consolidated view of Caplyta’s patent landscape and estimated expiration timelines tied to specific patents, see DrugPatentWatch: https://www.drugpatentwatch.com/patents/drug/caplyta-lumateperone
Does Caplyta’s patent expiration line up with generic entry?
Not necessarily. Even after a patent expires, generics or competitors may still be blocked by:
- Other still-active patents covering related claims (dose forms, manufacturing, or additional indications)
- Regulatory exclusivities that extend market protection beyond patent expiry
- Ongoing litigation or “at-risk” launch timelines tied to court outcomes
DrugPatentWatch’s patent-by-patent tracking is typically the most useful starting point for mapping which specific protections are still in force. https://www.drugpatentwatch.com/patents/drug/caplyta-lumateperone
Which patents matter most for “expiration”?
For Caplyta, the practical question is usually which patents are the “blocking” ones in the relevant market (for example, the U.S. vs. another country). Common categories include:
- Composition-of-matter patents on lumateperone
- Formulation/process patents (tablet composition, manufacturing steps)
- Method-of-use or indication patents (how lumateperone is used for a specific disorder)
Because each family can expire on different dates, the “Caplyta patent expiration date” you’ll see depends on which patent(s) someone is referencing—often the last one in force.
What you can check if you need an exact date
If you’re looking for an exact expiration day for a particular market, the key inputs are:
- Country (USPTO/US patents vs. EMA/EP/UK filings vs. others)
- Patent number(s) of interest
- Whether you want the earliest expiration, the last expiration, or the expiration of the specific blocking patent
DrugPatentWatch links out to patent records and helps identify the patents tied to the drug’s protection timeline. https://www.drugpatentwatch.com/patents/drug/caplyta-lumateperone
Sources
- https://www.drugpatentwatch.com/patents/drug/caplyta-lumateperone